INTRODUCTION
============

Prostate cancer (Pca) is the second most common cancer in males and ranks sixth in terms of cancer-related mortality \[[@B1]\]. The global incidence of Pca is increasing steadily, except in a few high-income countries \[[@B2]\]. In general, mortality caused by cancer can be reduced by early detection and treatment. Early detection through screening is recommended, but whether Pca screening lowers Pca mortality remains controversial. In particular, the effectiveness of population screening using prostate-specific antigen (PSA) rather than opportunistic screening performed for well-informed males in clinical situations is controversial, fueled by the discrepant results of the Prostate, Lung, Colorectal and Ovarian (PLCO) and the European Randomized study of Screening for Prostate Cancer (ERSPC), large-scale randomized controlled trials (RCTs) \[[@B3], [@B4]\].

Numerous reviews of the effectiveness of Pca population screening have reported disparate results. Djulbegovic et al. \[[@B5]\] and Ilic et al. \[[@B6]\] reviewed the effect of PSA with/without a digital rectal exam (DRE) and transrectal ultrasound (TRUS) in a meta-analysis. According to their results, such screening did not lower Pca-specific mortality but did increase diagnosis of stage 1 Pca (relative risk \[RR\], 1.95; 95% confidence interval \[CI\], 1.22-3.13). Lumen et al. \[[@B7]\] reported that PSA and DRE screening has no significant effect on Pca-specific mortality but did have a significant effect on the diagnosis of localized cancer (RR, 1.81; 95% CI, 1.15-2.86). PSA with/without DRE/TRUS has been evaluated as a screening tool in prior reviews. Although DRE is an important tool for Pca screening, 73% of patients report pain and discomfort while undergoing DRE, which leads to an increased rate of refusal to undergo screening \[[@B8]\]. PSA is simple and more relevant for screening than DRE or TRUS. Furthermore, a number of guidelines consider PSA to be a major screening test \[[@B9]-[@B11]\]. Therefore, the effectiveness of PSA screening alone should be assessed.

The accuracy of PSA in population-based screening has not been investigated and so no reference data are available for comparison, but the sensitivity of total PSA (tPSA) in typical clinical situations is 0.78-1. The specificity of tPSA is 0.06-0.66, depending on the cut-off used \[[@B12]\]. Despite such differences in accuracy, tPSA has the advantage of simplicity compared with other tests, making it the most commonly used Pca tumor marker \[[@B13]\].

In the present study, we assessed Pca-specific mortality and detection rate by systematic review and meta-analysis of prior systematic reviews to determine the effect on Pca screening of PSA without DRE and TRUS.

METHODS
=======

We systematically reviewed the methods of using existing systematic reviews to replace *de novo* by White et al. \[[@B14]\] to study the effectiveness of PSA for population-based Pca screening. We selected the most relevant reviews and conducted additional literature searches to identify the most recent studies.

1. Search strategy and selection criteria
-----------------------------------------

We determined PICOTS-SD (population, intervention, comparator, outcome, setting, and study design) in advance, and then searched databases to identify relevant systematic reviews. Predetermined PICOTS-SD was as follows.

Participants: asymptomatic males \>40 yr who underwent PSA population screening; no restrictions on region or race.

Intervention: tPSA.

Comparison: no screening or current practice.

Outcomes: overall mortality, Pca-specific mortality, diagnosis of Pca, stage of Pca at diagnosis.

We searched using the systematic review filter that was developed by the Scottish Intercollegiate Guideline Network. We restricted our search to the studies published in English or Korean. The following databases were searched: Cochrane Database of Systematic review, Ovid MEDLINE, Ovid EMBASE, and Centre of Reviews and Dissemination. Details of the search strategies are available as a supplemental data ([Table S1](#S1){ref-type="supplementary-material"} and [Table S2](#S2){ref-type="supplementary-material"}) on the ALM online ([www.annlabmed.org](http://www.annlabmed.org)).

Inclusion criteria were systematic reviews of high quality or health technology assessment reports or meta-analyses assessed using AMSTAR, including recently published large RCTs. We excluded narrative reviews and primary studies.

All studies were independently reviewed and selected by two researchers (YJ Lee and JE Park). Titles and abstracts were reviewed in duplicate and inappropriate studies were excluded. If a title or abstract appeared to meet the eligibility criteria for inclusion in the review, or we could not determine its eligibility, the full text of the article was obtained and evaluated to determine whether it met the inclusion criteria. Discrepancies between the reviewers were resolved by discussion.

The updated search for screening new RCTs was conducted until 1 yr prior, the last searching date for relevant systematic reviews (since January 2009). Indexing by PubMed-MEDLINE was noticeably more rapid, so we also searched PubMed. The searched databases were Ovid Medline, Ovid Embase, Cochrane Central Register of Controlled Trials, and PubMed. Participants, interventions, comparisons, and outcomes were as listed above. All randomized, quasi-randomized, and controlled trials were eligible for this review. Inclusion criteria were population screening trials using PSA. Trials of screening a symptomatic population were excluded.

All RCT articles were reviewed independently by two of the five researchers (SY Kim, YK Lee, BR Jeon, YJ Lee, and JE Park). Titles and abstracts were first reviewed, and inappropriate literature was excluded. The full text of each potentially eligible study was reviewed twice. All disagreements were resolved by discussion.

2. Quality assessment of the systematic review and risk of RCT bias
-------------------------------------------------------------------

The quality of the systematic reviews was assessed by two reviewers (YJ Lee and JE Park) who independently used the assessment of multiple systematic reviews (AMSTAR) tool of Shea et al. \[[@B15]\]. The RCTs were assessed using the risk of bias tool developed by the Cochrane group. Risk of bias was also independently assessed by two reviewers (each article was assigned to two of the four reviewers, SY Kim, YK Lee, BR Jeon, and JE Park).

3. RCT data extraction
----------------------

Data were extracted by two independent reviewers (each article was assigned to two of the five reviewers, SY Kim, YK Lee, BR Jeon, YJ Lee, and JE Park) using a standardized data extraction form. Any discrepancies were resolved by consensus or in consultation with a third reviewer. General information (including the name of the trial, the yr of publication, and country), such as mean age, inclusion criteria, PSA test method, reference standard, biopsy method, total number of participants, study period, follow-up period, and Pca diagnostic method were extracted from all trials.

4. Data synthesis
-----------------

Screening effectiveness was analyzed statistically by means of RR. If frequencies were provided by the RCTs, the Mantel-Haenszel method was used for statistical synthesis with a random effects model. If no frequencies were provided, inverse variance methods were used for the analysis. Results are presented as RRs and CIs. The Review Manager software (version 5.1, 2011; The Nordic Cochrane Center, the Cochrane Collaboration, Copenhagen, Denmark) was used for the synthesis.

5. Assessment of heterogeneity and sensitivity analysis
-------------------------------------------------------

Heterogeneity between studies was assessed using Cochrane\'s Q and I^2^ statistics. Publication bias could not be assessed using Egger\'s method \[[@B16]\] because \<10 trials were included. Subgroup analyses were conducted according to age (age ≥55 yr or all ages), follow-up period (PLCO 7 yr of follow-up or 10 yr), and overall risk of bias (only those with a low risk of bias or all), taking into consideration the characteristics of the included studies.

6. Level of evidence
--------------------

The tool of Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the level of evidence and summarize each outcome. The GRADEprofiler software (Version 3.6 for Windows, 2008: The Cochrane Collaboration, Copenhagen, Denmark) was used.

RESULTS
=======

1. RCTs included
----------------

The identification and selection procedure for the systematic reviews is shown in a flow diagram ([Fig. 1](#F1){ref-type="fig"}). We selected RCTs using existing systematic reviews. A total of 206 publications were identified by searching the databases; however only two of these were eligible for systematic review \[[@B5], [@B6]\]; these were of high quality as assessed by AMSTAR. Seven RCTs were reviewed in these two systematic reviews \[[@B3], [@B4], [@B17]-[@B21]\]. An updated search was performed, which took as its starting point the end of the search periods of the two included systematic reviews. We included a new article from this updated search, the Norrköping trial, which incorporated a long-duration follow-up period \[[@B22]\].

We included six of the eight RCTs ([Table 1](#T1){ref-type="table"}). The Stockholm trial was excluded because it did not investigate the effect of PSA screening \[[@B20]\]. The 2004 Norrköping study was not included due to inclusion of the more up-to-date version of that study. Because unlike in other trials, fine-needle aspiration was used for biopsy in the Norrköping study, this trial was included only in the sensitivity analysis. The characteristics of the individual trials are shown in [Table 2](#T2){ref-type="table"}.

2. Risk of bias of the included RCTs
------------------------------------

The RCTs were assessed using the Cochrane\'s risk of bias tool ([Fig. 2](#F2){ref-type="fig"}). Three studies had a low risk of bias due to their random sequence generation domain. The risks of bias of the other three studies were unclear. Predetermined outcomes were objective, given the mortality and diagnosis. Thus, we assessed low risks of bias for all outcomes in the blinding domain.

3. Effect on mortality
----------------------

The Pca-specific mortality rate did not differ between the screening and the control groups ([Table 3](#T3){ref-type="table"}). The Göteborg trial included duplicate data with the ERSPC, so we included only data from the 60-64-yr age group in the Göteborg trial \[[@B17]\]. The PLCO trial reported Pca-specific mortality rates after 7 and 10 yr \[[@B3]\]. We analyzed both data sets but found little difference. The RR was 0.91 (95% CI, 0.80-1.04, *P*=0.17) for the 7-yr PLCO follow-up and 0.93 (95% CI, 0.81-1.07, *P*=0.31) for the 10-yr PLCO follow-up.

All-cause mortality data were available in the Göteborg, PLCO, and ERSPC trials (ERSPC was quoted from the study by Ilic \[[@B6]\]; data for only the 60-64 yr age group were extracted from the Göteborg trial). No difference in all-cause mortality was observed between the screening and control groups (RR, 0.99; 95% CI, 0.98-1.01, *P*=0.50).

4. Effect on diagnosis
----------------------

Four trials, which included 351,531 randomized participants, contributed information on the Pca diagnosis. In the meta-analysis, the screening group was 46% more likely to be diagnosed with Pca in the 7-yr PLCO follow-up data. The screening group in the 10-yr PLCO follow-up data was 45% more likely to be diagnosed with Pca.

Diagnostic data according to stage were extracted from three available trials: the ERSPC, French ERSPC, and the PLCO \[[@B3], [@B4], [@B19]\]. A total of 3,749 early cancers were detected in 153,823 screening participants, and 1,907 early cancers were detected in 169,894 control participants. Pca diagnosis at stages 1, 2, and all other stages showed marked heterogeneity, I^2^\>90%.

Pca diagnosis at stage 1 in the screening and control groups was not different (RR, 1.67; 95% CI, 0.95-2.94, *P*=0.07); however, the diagnosis of Pca at stage 1 presented the same direction of effect in all trials, despite the marked heterogeneity.

The screening group was 39% more likely to be diagnosed with stage 2 Pca than the control group (RR, 1.39; 95% CI, 1.33-1.45, *P*\<0.001) in the three trials, but with marked heterogeneity.

Pca screening did not increase the number of subjects diagnosed with stages 3 or 4 Pca. A random-effects model for the meta-analysis showed a RR of 0.94 (95% CI, 0.85-1.04, *P*=0.24).

5. Subgroup analysis
--------------------

A subgroup analysis was performed according to age, follow-up period, and risk of bias. The outcomes were Pca-specific mortality and diagnosis of Pca at all stages. Other factors did not affect the results significantly ([Table 4](#T4){ref-type="table"}).

6. Level of evidence
--------------------

The levels of evidence as determined by GRADE were from very low to moderate ([Table 5](#T5){ref-type="table"}). None of the studies reported the randomization sequence or allocation concealment methods, so all outcomes were initially downgraded. The inconsistency domain was downgraded at the outcome of Pca diagnosis, diagnosis of stage 1 Pca, and diagnosis of stage 2 Pca. In addition, the imprecision domain was downgraded at the diagnosis of stage 2 Pca with a wide CI for the effect size.

DISCUSSION
==========

The ERSPC, a recent large-scale clinical PSA screening study, reported the results of 11 yr of follow-up \[[@B23]\]. The PLCO reported updated results of 13 yr of follow-up \[[@B24]\]. However, these two large-scale studies showed inconsistent results. The PLCO reported a RR of 1.09 (95% CI, 0.87-1.36) for Pca-specific mortality after 13 yr of follow-up and the ERSPC reported a RR of 0.79 (95% CI, 0.68-0.91) after 11 yr of follow-up. Controversies over the effectiveness of screening are found not only in clinical studies but also in related guidelines. While the European Association of Urology does not recommend population screening, the Japanese Urological Association (JUA) recommends PSA as a Pca screening test for males age \>50 yr \[[@B9], [@B10]\]. JUA recommends PSA screening because the screening rate in Japan is very low. Some observational studies have reported a high mortality-reduction effect; however, these had limitations in that they failed to consider the results of large-scale clinical trials \[[@B9]\]. In the midst of these controversies, USPSTF commented that PSA-based screening does not affect Pca-specific mortality much and may even inflict unnecessary harm. Therefore, Pca screening should be discouraged as Grade D \[[@B25]\].

The detection rate of early Pca stages was high in the screening group, with a RR of 1.95 (95% CI, 1.22-3.13), and Pca-specific mortality was not significantly lower, according to the review by Djulbegovic et al. \[[@B5]\]. However, our findings indicate that screening did not increase early stage detection of Pca and did not lower the risk of death. The rate of detection of early stage cancer by population screening was not significantly higher (RR=1.67; 95% CI, 0.95-2.94). This difference could be explained in several ways. In contrast to prior studies, we reviewed the effect of PSA screening only; thus, the included studies were distinguished from prior systematic reviews. Among DRE, PSA, and TRUS as common screening tools, PSA was considered more suitable due to its simplicity. DRE and TRUS can cause pain and discomfort to examinees, reducing the rate of participation in screening. Population-based screening for five cancers is conducted in Korea. The rate of participation in liver cancer screening in Korea was 32.6% in 2008 and 37.9% in 2009 using a simple approach such as blood sampling \[[@B26]\]. The rate of participation in gastric cancer screening using an invasive method such as endoscopy was 20.5% from 2005 to 2006 \[[@B27]\]. Despite the high rates of mortality and disease burden due to gastric cancer in Korea, the method of screening influences the participation rate, so we investigated the effectiveness of PSA as a screening tool. This systematic review was conducted using existing systematic reviews. We examined five trials of the effectiveness of PSA-based population screening in existing systematic reviews and additional literature searches. This method facilitated cross-checking of the omitted studies and acquisition of data from unpublished reports \[[@B14]\]. The detection rate heterogeneity between a previous review and our findings was high, although the direction of effect was identical, indicating that the results should be interpreted with caution.

Pca-specific mortality had a RR of 0.88 (95% CI, 0.71-1.09) in Djulbegovic et al. \[[@B5]\], and a RR of 0.95 (95% CI, 0.85-1.07) in Ilic et al. \[[@B6]\]; the difference was not significant. Similarly, PSA-based population screening did not reduce specific mortality and all-cause mortality in this study. In contrast, the rate of detection of all Pca stages was 45% higher in the screening group than in the non-screening group. This result was similar to that when the PLCO was switched from 7 to 10 yr of follow-up data, and when the Göteborg research data for the 50-64-yr age group were included \[[@B3], [@B17]\]. In addition, no significant difference was observed in the sub-group analysis when studies were divided into those with a follow-up period \>10 yr and those with a follow-up \<10 yr, into those including all age groups and those including only the \>55-yr age group, and into those with high risk of bias and those without. The results of long-term follow-up in the ERSPC and PLCO trials were published in 2012 \[[@B23], [@B24]\]. These were not included because our search was conducted in 2011. Although not presented here, the detection rates of all-stage and Pca-specific mortality updated with data in 2012 (RR, 1.39; 95% CI, 1.13-1.72 and RR, 0.96; 95% CI, 0.79-1.15) were not significantly different from these results (RR, 1.45; 95% CI, 1.13-1.85 and RR 0.93; 95% CI, 0.81-1.07, respectively).

These results suggest overdiagnosis because the progress of Pca is in many cases slow, particularly during the early stage \[[@B28]\]. A larger number of patients with cancer should be qualified in the screening group in a random allocation, compared to a clinical trial of screening, to demonstrate the presence of overdiagnosis. After the end of the clinical trial, more patients with cancer should be present in the control group; thus the difference between the control and screening groups should be reduced (catch-up cancer). This has been demonstrated for breast and lung cancers, indicating overdiagnosis. The existence of overdiagnosis of Pca is unclear due to the short follow-up periods \[[@B28]\]. Although calculating the accuracy of overdiagnosis of Pca is difficult, some studies have estimated the rate based on data from representative clinical trials. The overdiagnosis rate estimated in the study quoted most frequently (ERSPC) was 66% \[[@B29]\]. Another possible explanation is that the actual benefit of screening might not be found due to the short follow-up periods. If the early detection period of Pca is 5.4-6.4 yr, as estimated by some studies \[[@B29]\], the follow-up period in studies published to-date may be somewhat short. However, the mean follow-up period in a number of studies was \>10 yr (Quebec, Norrköping, PLCO, and Göteborg) \[[@B3], [@B17], [@B18], [@B22]\]. Indeed, addition of 11 yr of follow-up in the ERSPC had no effect on the results (data not shown) \[[@B23]\]. Therefore, it is unlikely that a short follow-up period leads to a lack of benefit. In contrast to our finding that screening increased the Pca detection rate but did not lower the risk of death, a recent study concluded that screening increases the detection rate and lowers the risk of death \[[@B7]\]. Lumen et al. conducted an adjusted analysis, excluding studies with a follow-up period \<8 yr and those in the control group with a degree of contamination \>33.3% \[[@B7]\]. As the possibility of contamination in most studies is high, although not reported, and there are no established criteria for an acceptable degree of contamination, analysis of contamination excluding the PLCO trial is difficult. Furthermore, the ERSPC follow-up period differed among countries. In 2012, follow up was \<8 yr in some centers. Thus, caution should be used when interpreting the results of an adjusted analysis.

The level of evidence for all-cause and Pca-specific mortality was moderate, as assessed using the GRADE method. The level of evidence for the diagnosis of Pca was also low. An important reason for the low level of evidence for Pca is heterogeneity. That is, the heterogeneity of the studies was not problematic, with the exception of Pca diagnosis. The variability in the Pca diagnosis results was high (I^2^=98%), but should be accepted because the direction of effect was identical, the effect size was relatively large, and the CI was narrow.

Three studies (PLCO, ESRPC, and Göteborg) were rated to have a low risk of bias, while the French ERSPC and Quebec studies had a high or uncertain risk of bias \[[@B3], [@B4], [@B17]-[@B19]\]. The risk of bias was uncertain in the Norrköping trial, which was included in the sensitivity analysis \[[@B22]\]. Among the risks of bias, the degree of contamination, which indicates the screening test rate in the control group, can be an important issue in screening. The degree of contamination was circa twice as high in the PLCO than in the ERSPC trials \[[@B3], [@B30]\]. Other studies did not mention the degree of contamination; however, it is highly likely that most studies had a contamination problem. Because contamination negates the benefit of screening, it can be an important source of bias. As it is not reported by many studies, we could not conduct a sub-group analysis based on the degree of contamination.

Caution should be used when interpreting our results, as we examined the effectiveness of screening asymptomatic subjects who participated in population screening programs rather than the effectiveness of screening among high-risk groups or of hospital-based screening by physicians. Moreover, the incidence of Pca varies among races and countries. Although the studies were not limited to specific races, they were conducted in Europe and the US. Therefore, if our results are to be used as a basis for a screening recommendation in Asia, a number of factors should be considered. A large RCT with Asian population is required to determine the effectiveness of PSA screening.

CONCLUSIONS
===========

PSA screening did not increase early detection of Pca and did not lower the risk of death. Thus PSA screening was ineffective but did indicate risks caused by overdiagnosis. Thus, the necessity of a national PSA screening program should be reviewed carefully with due consideration of the results of future studies.
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Comparison of the included randomized controlled trials (RCTs)
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Characteristics of the included randomized controlled trials (RCTs)
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ERSPC: Included duplicate Göteborg data (those born in 1930-939), but used only part of the Göteborg data (those born in 1940-1944); ERSPC: Inclusion criteria age was 50-74 yr, but only those 55-64 yr were included in the study. Both data extracted in this study; PLCO: each reported data of 7-and 10-yr follow-up; Norrköping trial: Included only in the sensitivity analysis.

Abbreviations: NA, Not assessed; PSA, Prostate specific antigen; DRE, digital rectal exam.
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Effects of total prostate-specific antigen (tPSA) screening on mortality and diagnosis
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^\*^ERSPC (50-74 yr) 2009 \[[@B4]\], Göteborg (60-64 yr) 2010 \[[@B17]\], PLCO (55-74 yr) 2009 \[[@B3]\], Quebec (45-80 yr) 2004 \[[@B18]\]; ^†^ERSPC (50-74 yr) 2009 \[[@B4]\], Göteborg (60-64 yr) 2010 \[[@B17]\], PLCO (55-74 yr) 2009 \[[@B3]\]; ^‡^ERSPC (50-74 yr) 2009 \[[@B4]\], French ERSPC (55-69 yr) 2009 \[[@B19]\], Göteborg (60-64 yr) 2010 \[[@B17]\], PLCO (55-74 yr) 2009 \[[@B3]\]; ^§^ERSPC (50-74 yr) 2009 \[[@B4]\], French ERSPC (55-69 yr) 2009 \[[@B19]\], PLCO (55-74 yr) 2009 \[[@B3]\].

Abbreviation: Pca, Prostate cancer.
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Results of subgroup analysis
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Abbreviations: NA, not applicable; f/u, follow up; RR, Relative risk; M-H, Mantel-Haenszel.

###### 

Level of evidence assessed by GRADE
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High: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate: Further research is likely to have an important impact on our confidence in the estimate of effect and my change the estimate.

Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

Abbreviations: Pca, Prostate cancer; GRADE, Grading of Recommendations Assessment, Development and Evaluation.
